Cell Surface Mucins In Gastrointestinal Infection, Inflammation And Cancer Development
Funder
National Health and Medical Research Council
Funding Amount
$469,627.00
Summary
Cell surface mucins are protective molecules that line all the wet surface of the body, including the gastrointestinal tract. Our research has uncovered that mucins regulate cell growth and cell death. Inappropriate control by the mucins, could lead to chronic inflammation and formation of cancers. We will test how important these molecules are in the development of cancers in the intestine, and further explore the mechanism of action.
Tuberculosis is one of the most threatening infectious diseases worldwide due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to interrogate two previously neglected immune mechanisms and their potential to enhance vaccine-induced immunity by incorporating these mechanisms into new genetically modified BCG strains. We will also investigate alternative BCG vaccination routes to generate long-lived immune cells that can rapidly control the infection.
DsbA Foldases From Multidrug Resistant Pathogens As Targets For New Antimicrobials
Funder
National Health and Medical Research Council
Funding Amount
$743,401.00
Summary
Bacteria that cause common human infections, such as cystitis and diarrhoea, are now resistant to many antibiotics. If no action is taken, by 2050 antibiotic resistant infections will kill more people each year than cancer. This project aims to address this global public health crisis by characterising promising new bacterial targets and inhibitors designed to disarm multidrug resistant pathogens. Longer term this work could provide new infection therapies that are urgently needed.
ADding Negative PRESSure To Improve HealING (the DRESSING Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,380,446.00
Summary
The aim of this 5-year randomised comtrolled trial is to test the clinical and cost effectiveness of vacuum dressings in reducing the incidence of surgical site infection in obese women undergoing elective and semi-urgent caesarian section. The trial will be conducted at 4 hospitals in south east Queensland. 2,100 women undergoing caesarian section will either receive a vacuum or standard surgical dressing and will be followed for 1 month after surgery.
Antibiotic resistance is a looming public health crisis. New antibiotics with new mechanisms of action are desperately needed. The long-term goal of this research is to develop new drugs that disarm bacteria to overcome the problem of antibiotic resistance.
Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.
The SAVE Trial: Securing All IntraVenous Devices Effectively In Hospitals. A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$980,393.00
Summary
Going to hospital usually means having an IV drip in your hand or arm vein. Almost half of all IV drips fall out or fail because they are not well secured to the skin. This means patients miss out on treatment and have additional painful needlesticks to insert new devices. Serious infections can also occur. This study will find the best dressings to use on IV drips. Patients will have their drips glued in with medical superglue, or have one of two new dressings, compared with current usual care.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Inhibition Of IFN-?/? By Human Metapneumovirus And The Induction Of Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$605,251.00
Summary
The newly isolated human metapneumovirus (hMPV) causes significant respiratory illness in infants, young children and the elderly. The virus can persist long-term and may predispose individuals to chronic lung disease. This proposal aims to determine the mechanisms by which hMPV infection causes respiratory disease, with a view to improving treatments and preventing disease.
Intravascular Device Administration Sets: Replacement After Standard Versus Prolonged Use (The RSVP Trial)
Funder
National Health and Medical Research Council
Funding Amount
$1,611,239.00
Summary
Most hospital patients need an IV drip, a small plastic tube in a vein, often the hand/arm. 14 million/yr are used in Australia. IV drips are connected to plastic tubing through which fluid & medicine is given. IV tubing is needed for a week or more, but is only used for 3-4 days as it was thought this might prevent infection. It is now thought that IV tubing can be used for a week. This would save $1 billion/year & reduce nurses workload. The research will test the safety of this approach.